Viewing Study NCT04674956


Ignite Creation Date: 2025-12-24 @ 11:36 PM
Ignite Modification Date: 2026-03-04 @ 7:43 PM
Study NCT ID: NCT04674956
Status: RECRUITING
Last Update Posted: 2024-04-02
First Post: 2020-12-15
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Sponsor: RenJi Hospital
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Cancer Stage IV View
None Pancreatic Cancer Metastatic View
Keywords: